188 related articles for article (PubMed ID: 21735833)
1. [Attempts to treat chronic hepatitis C with HCV protease inhibitor].
Pawłowska M
Przegl Epidemiol; 2011; 65(1):35-8. PubMed ID: 21735833
[TBL] [Abstract][Full Text] [Related]
2. New HCV therapies on the horizon.
Vermehren J; Sarrazin C
Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
[TBL] [Abstract][Full Text] [Related]
3. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
4. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
Ferenci P; Reddy KR
Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
[TBL] [Abstract][Full Text] [Related]
5. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients.
Burney T; Dusheiko G
Expert Rev Anti Infect Ther; 2011 Feb; 9(2):151-60. PubMed ID: 21143041
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic hepatitis C.
Bihl F; Negro F
Minerva Med; 2009 Dec; 100(6):459-65. PubMed ID: 20010481
[TBL] [Abstract][Full Text] [Related]
7. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
Foote BS; Spooner LM; Belliveau PP
Ann Pharmacother; 2011 Sep; 45(9):1085-93. PubMed ID: 21828346
[TBL] [Abstract][Full Text] [Related]
8. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
[TBL] [Abstract][Full Text] [Related]
9. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.
Pawlotsky JM
Hepatology; 2011 May; 53(5):1742-51. PubMed ID: 21374691
[TBL] [Abstract][Full Text] [Related]
10. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
[TBL] [Abstract][Full Text] [Related]
11. Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.
de Bruijne J; Thomas XV; Rebers SP; Weegink CJ; Treitel MA; Hughes E; Bergmann JF; de Knegt RJ; Janssen HL; Reesink HW; Molenkamp R; Schinkel J
J Viral Hepat; 2013 Nov; 20(11):779-89. PubMed ID: 24168257
[TBL] [Abstract][Full Text] [Related]
12. Boceprevir: a protease inhibitor for the treatment of hepatitis C.
Chang MH; Gordon LA; Fung HB
Clin Ther; 2012 Oct; 34(10):2021-38. PubMed ID: 22975763
[TBL] [Abstract][Full Text] [Related]
13. Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.
Sanjo M; Saito T; Ishii R; Nishise Y; Haga H; Okumoto K; Ito J; Watanabe H; Saito K; Togashi H; Fukuda K; Imai Y; El-Shamy A; Deng L; Shoji I; Hotta H; Kawata S
J Med Virol; 2010 Aug; 82(8):1364-70. PubMed ID: 20572079
[TBL] [Abstract][Full Text] [Related]
14. Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?
Zeuzem S; Nelson DR; Marcellin P
Antivir Ther; 2008; 13(6):747-60. PubMed ID: 18839776
[TBL] [Abstract][Full Text] [Related]
15. New treatments for chronic hepatitis C virus infection.
Corouge M; Pol S
Med Mal Infect; 2011 Nov; 41(11):579-87. PubMed ID: 21764234
[TBL] [Abstract][Full Text] [Related]
16. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
[TBL] [Abstract][Full Text] [Related]
17. Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
Larrey D; Carenco C; Guyader D; Boyer N; Benhamou Y; Pageaux GP; Rouzier R; Marcellin P
Antivir Ther; 2012; 17(5):927-32. PubMed ID: 22611092
[TBL] [Abstract][Full Text] [Related]
18. Telaprevir for the treatment of chronic hepatitis C infection.
Muir AJ
Expert Rev Anti Infect Ther; 2011 Dec; 9(12):1105-14. PubMed ID: 22114960
[TBL] [Abstract][Full Text] [Related]
19. Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment.
de Bruijne J; Sullivan JC; Kieffer TL; Botfield M; Shames B; Schinkel J; Molenkamp R; Weegink C; Reesink H
J Clin Virol; 2012 Feb; 53(2):174-7. PubMed ID: 22138301
[TBL] [Abstract][Full Text] [Related]
20. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.
Zhou YQ; Wang XH; Hong GH; Zhu Y; Zhang XQ; Hu YJ; Mao Q
J Viral Hepat; 2011 Aug; 18(8):595-600. PubMed ID: 21105968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
